This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cocozza, M. Articles by Milani, M. Search for Related Content PubMed PubMed Citation Articles by Cocozza, M. Articles by Milani, M.

(Stroke. 1995;26:597-601.)
© 1995 American Heart Association, Inc.

Articles

Effects of Picotamide, an Antithromboxane Agent, on Carotid Atherosclerotic Evolution

A Two-Year, Double-Blind, Placebo-Controlled Study in Diabetic Patients

Manlio Cocozza, MD; Tommaso Picano, MD; Ugo Oliviero, MD; Nicola Russo, MD; Vincenzo Coto, MD Massimo Milani, MD

From the IV Division of Internal Medicine, University of Naples; and the Cardiovascular Department, Sandoz Prodotti Farmaceutici SpA (M.M.), Milan, Italy.

Correspondence to Massimo Milani, MD, Cardiovascular Medical Department, Sandoz Prodotti Farmaceutici SpA, Via Arconati 1, 10135 Milano, Italy.

Background and Purpose We assessed the effects of long-term treatment with picotamide, an antiplatelet agent with dual antithromboxane activity, on the evolution of early asymptomatic carotid atherosclerotic lesions in diabetic patients.

Methods In a double-blind, placebo-controlled, 2-year study, 50 type II normotensive diabetic patients (35 men; mean age, 66±5 years) with asymptomatic mild or moderate nonstenotic (<50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events were enrolled and randomly given picotamide (300 mg TID) or the corresponding placebo. A high-resolution, real-time B-scan echographic assessment of carotid arteries was performed at baseline and after 1, 3, 6, 12, 18, and 24 months of double-blind treatment. Prevalence and evolutionary trends of carotid atherosclerotic lesions (number per patient and mean stenosis expressed as percent) were considered as efficacy primary end points.

Results At baseline, mean±SD numbers of carotid atherosclerotic lesions per patient were 2.7±1.8 and 2.2±1.2 in the picotamide and placebo groups, respectively. Mean±SD percent stenosis was 25.3±7% in the picotamide group and 27.3±6% in the placebo group. Forty-nine patients completed the study. At month 24, the placebo group (n=24) showed a significant progression in number of carotid atherosclerotic lesions (3.04±1.8; P<.02 versus baseline) and in mean percent stenosis (35±17%; 95% confidence interval, 33% to 37%; P<.01 versus baseline). In the picotamide group (n=25), mean number of carotid atherosclerotic lesions (2.7±1.6) and percent stenosis (26±9%; 95% confidence interval, 24.8% to 27.2%) remained unchanged. At month 24, compared with randomized placebo, lesion numbers (P<.03) and percent stenosis (P<.01) in the picotamide group were significantly lower. During the study, 12 patients experienced major or minor ischemic vascular events (9 in the placebo group and 3 in the picotamide group; P=.07).

Conclusions In diabetic patients compared with patients receiving placebo, long-term treatment with picotamide can slow the evolution of early carotid atherosclerotic lesions, inhibiting progression of plaque number and growth.

Key Words: thromboxane antagonist • antiplatelet agents • carotid artery disease • diabetes mellitus • ultrasonics

This article has been cited by other articles:

				M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]

				W. R Hiatt and M. J Krantz Masterclass series in peripheral arterial disease: Antiplatelet therapy for peripheral arterial disease and claudication Vascular Medicine, February 1, 2006; 11(1): 55 - 60. [Abstract] [PDF]

				G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]

				S. Castellani, R. Paniccia, C. Di Serio, G. La Cava, L. Poggesi, S. Fumagalli, G. F. Gensini, and G. G. Neri Serneri Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure J. Am. Coll. Cardiol., July 2, 2003; 42(1): 133 - 139. [Abstract] [Full Text] [PDF]

				M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119 (2009): 283S - 299S. [Full Text] [PDF]

				B. Capaldo, L. Patti, U. Oliviero, S. Longobardi, F. Pardo, F. Vitale, S. Fazio, F. Di Rella, B. Biondi, G. Lombardi, et al. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1378 - 1381. [Abstract] [Full Text] [PDF]